Nymox shares soar on late-stage BPH drug licensing deal

Shares of Nymox ($NYMX) raced up 35 percent in pre-market trading this morning after investors learned of its deal to license a late-stage therapy for benign prostatic hyperplasia to Italy's Recordati. The New Jersey biotech gets $13 million upfront and unspecified milestones in exchange for the European rights to NX-1207, now in a Phase III U.S. study.

In addition to the fees and milestones, Nymox also stands to earn royalties on a sliding scale that starts at 26 percent and can rise to 40 percent. "Recordati has a long history in Europe of clinical, regulatory and commercial expertise and has provided a strong commitment to the development and marketing of NX-1207," says Nymox CEO Paul Averback.

A locally injected drug, Nymox has boasted that in earlier trials "a single dose of NX-1207 has been found to produce very promising symptomatic improvements without causing the sexual or cardiovascular side effects associated with currently approved drugs."

Nymox has been on a roll recently. Just a couple of weeks ago the biotech announced that it had raised $15 million from institutional investors. The financing followed an announcement that in a late-stage study "a single administration of NX-1207 2.5 mg has produced on average improvements in the standardized BPH symptom score (8-10 points at 90 days) that were approximately double that reported for currently approved BPH drugs (3-5 points)."

- here's the Nymox release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.